Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity

Dulaglutide treatment resulted in reductions in binge eating scale score, body mass index, weight, and binge eating disorder symptoms after 6 weeks.

• The patient had baseline assessments of binge eating scale score, glycated hemoglobin level, body mass index (BMI), and weight.
• After 6 weeks of dulaglutide 0.75 mg once weekly, improvements in binge eating disorder symptoms and other metrics were noted.
• Dulaglutide was well tolerated, with no reported adverse drug events.
• The findings suggest potential for GLP-1 receptor agonists in managing binge eating disorder alongside obesity and type 2 diabetes.

AI simplified